Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

SHA:688621 Revenue

Beijing Sun-Novo Pharmaceutical Research had revenue of 229.04M CNY in the quarter ending June 30, 2026, a decrease of -36.28%. This brings the company's total for the last twelve months to 1.06B, down -4.32% year-over-year. In the year 2025, Beijing Sun-Novo Pharmaceutical Research had annual revenue of 1.22B with 13.33% growth. That makes Beijing Sun-Novo Pharmaceutical Research the 19,186th largest company in the world by revenue and 3,501st in China.

• Revenue (ttm): 1.06B
• Revenue Growth: -4.32%
• P/S Ratio: 5.97
• Revenue / Employee: 957.54K
• Employees: 1,105
• Market Cap: 6.32B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Clinical Trials and Bioanalytical Services 522.56M 42.8%
• Pharmacy Research Services 338.48M 27.7%
• Innovative Drugs and Improved New Drugs 248.36M 20.4%
• Intellectual Property Licensing 100.00M 8.2%
• Equity Sharing 10.94M 0.9%

Fiscal year ended Dec 31, 2025 See the full SHA:688621 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.22B	143.77M	13.33%
Dec 31, 2024	1.08B	146.35M	15.70%
Dec 31, 2023	932.12M	255.51M	37.76%
Dec 31, 2022	676.61M	182.96M	37.06%
Dec 31, 2021	493.65M	146.29M	42.12%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error